期刊
MELANOMA RESEARCH
卷 24, 期 2, 页码 99-107出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CMR.0000000000000043
关键词
urokinase-type plasminogen activator receptor; melanoma cell; matrix metalloproteinase-2; urokinase-type plasminogen activator; matrix metalloproteinase-9; beta-elemene
beta-Elemene has been reported to be effective for the treatment of leukemia and certain solid tumors in basic and clinical studies. However, the mechanism of action of this phytochemical remains unknown. This study aimed to investigate the effect and mechanism of beta-elemene in the mouse melanoma cell line B16F10. Cell viability was measured using the MTT assay. beta-Elemene inhibited B16F10 melanoma cell metastasis, examined using scratch and Transwell migration/invasion assays. The mRNA and protein expression of urokinase-type plasminogen activator (uPA), the uPA receptor (uPAR), matrix metalloproteinase (MMP)-2, and MMP-9 were assayed using real-time PCR, immunocytochemistry, and western blotting methods. The results indicated that beta-elemene inhibited the viability of B16F10 melanoma cells in a dose-dependent and time-dependent manner. The migratory and invasive capacities of B16F10 cells were also inhibited by beta-elemene. The expression of uPA, uPAR, MMP-2, and MMP-9 was reduced by beta-elemene at both the mRNA and protein level. beta-Elemene inhibits the metastasis of B16F10 melanoma cells through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9. Thus, beta-elemene is a natural potential anticancer drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据